Novel Devices for Studying Acute and Chronic Mechanical Stress in Retinal Pigment Epithelial Cells by Farjood, Farhad & Vargis, Elizabeth
Novel Devices for Studying Acute and Chronic Mechanical Stress in Retinal 1 
Pigment Epithelial Cells 2 
 3 
Farhad Farjood1, Elizabeth Vargis1* 4 
 5 
1. Department of Biological Engineering, Utah State University, 4105 Old Main Hill, Logan, UT 6 
84322, USA 7 

















Choroidal neovascularization (CNV) is a major cause of blindness in patients with age-related 25 
macular degeneration (AMD). Overexpression of vascular endothelial growth factor (VEGF), a 26 
potent angiogenic protein, by retinal pigment epithelial (RPE) cells is a key stimulator of CNV. 27 
Mechanical stress occurs during different stages of AMD and is a possible inducer of VEGF 28 
expression in RPE cells. However, robust and realistic approaches to studying acute and chronic 29 
mechanical stress under various AMD stages do not exist. The majority of previous work has 30 
studied cyclic stretching of RPE cells grown on flexible substrates, but an ideal model must be 31 
able to mimic localized and continuous stretching of the RPE as would occur in AMD in vivo. To 32 
bridge this gap, we developed two in vitro devices to model chronic and acute mechanical stress 33 
on RPE cells during different stages of AMD. In one device, high levels of continuous 34 
mechanical stress were applied to focal regions of the RPE monolayer by stretching the 35 
underlying silicon substrate to study the role of chronic mechanical stimulation. In the second 36 
device, RPE cells were grown on porous plastic substrates and acute stress was studied by 37 
stretching small areas. Using these devices, we studied the effect of mechanical stress on VEGF 38 
expression in RPE cells. Our results suggest that mechanical stress in RPE cells induces VEGF 39 
expression and promotes in vitro angiogenesis. These results confirm the hypothesis that 40 
mechanical stress is involved in the initiation and progression of CNV. 41 
 42 
1. Introduction 43 
Retinal degeneration due to abnormal neovascularization occurs in many ocular diseases, 44 
including age-related macular degeneration (AMD).1,2 AMD is classified into two major types: 45 
dry (non-neovascular) and wet (neovascular). Dry AMD is characterized by the formation of 46 
lipid deposits (known as drusen) under the retinal pigment epithelium (RPE).3,4 In wet AMD, 47 
damage to retinal layers is caused by newly-formed blood vessels that invade the retina in a 48 
condition known as choroidal neovascularization (CNV), which can lead to irreversible vision 49 
loss.5,6 The choroid contains the vasculature in the healthy eye and is separated from 50 
photoreceptors by two intermediary layers: Bruch’s membrane (BrM) and the RPE (Figure 1). 51 
Photoreceptors are central to vision and their primary function is to transduce light into neural 52 
signals.7 RPE cells play an essential role in maintaining photoreceptor function by providing 53 
nutrients and growth factors and by phagocytosing photoreceptor outer segments.8 Under normal 54 
conditions, the RPE also regulates the growth of new blood vessels in the choroid via a repertoire 55 
of pro- and anti-angiogenic factors.9–12 The initiation and progression of CNV is believed to be 56 
driven primarily by the elevated expression of pro-angiogenic proteins in the RPE.10,13–15 57 
 58 
 
Figure 1. Schematic of the photoreceptors-RPE-choroid complex. (A) Healthy 
retina. (B) Chronic mechanical stress to RPE cells due to drusen formation in dry 
AMD. (C) Acute mechanical stress to RPE cells due to the invasion of blood vessels 
during CNV in wet AMD. 
Vascular endothelial growth factor (VEGF) is the most commonly implicated potent pro-59 
angiogenic factor in stimulating CNV initiation and progression. Normal levels of RPE-derived 60 
VEGF are essential for maintaining the vasculature of the choroid. However, increased secretion 61 
of VEGF by RPE cells can result in CNV.16–19 Although the exact causes of VEGF 62 
overexpression in RPE cells are not completely understood, several factors, such as hypoxia, 63 
oxidative stress, inflammation and exposure to blue light are known contributors.20–27 64 
Components of drusen, such as amyloid β and complement factors C3a and C5a, have also been 65 
shown to induce VEGF expression.28,29 More recently, the loss of intercellular junctions (multi-66 
protein complexes involved in cell-cell adhesion) of the RPE was found to elevate VEGF 67 
expression by RPE cells.30–32 68 
 69 
Another plausible contributor to CNV pathogenesis is excessive mechanical stress on the RPE, 70 
which might occur at different rates and in different stages of disease progression. One of the 71 
early signs of AMD is the formation of drusen in the BrM and under the RPE.33–35 While the 72 
components of drusen can induce VEGF expression in RPE cells, the increase in the size of 73 
drusen during the course of AMD can also contribute to the AMD pathogenesis by adding a 74 
continuous mechanical stress on the overlying layers (chronic stress, Figure 1.B). Drusen 75 
deposits grow in size with age and gradually elongate the RPE, often detaching it from its basal 76 
membrane.4,36,37 Depending on the drusen size and pattern of drusen distribution, up to 53% of 77 
dry AMD cases eventually progress to wet AMD.38 The risk of developing CNV has been shown 78 
to be higher in eyes with larger drusen, suggesting a role for chronic stretching of the RPE in 79 
CNV.3,39,40 In the more advanced form of AMD (wet AMD), invasion by newly-formed blood 80 
vessels, a hallmark of CNV, has already begun, so the elongation of the RPE takes place at a 81 
faster rate (acute stress, Figure 1.C), suggesting a role for acute stress.41–43  82 
 83 
While the growth in drusen size is slow and typically occurs over long periods of time (years),44 84 
at certain time points, faster drusen progression (months) may occur.44,45 The mechanical stress 85 
exerted on the RPE during CNV due to the growth of blood vessels and hemorrhage can occur 86 
within hours.46 Evaluating the effects of stress exerted to the RPE at different rates is therefore 87 
important in understanding the precursors and eventual progression of AMD. However, robust in 88 
vitro testing of realistic loading scenarios remains a technical challenge. Many previous studies 89 
used vacuum-induced equibiaxial stretching of RPE cells cultured on elastic membranes.47–49 90 
Other attempts to mimic in vivo mechanical stress include using magnetic force, elongating 91 
silicon membranes in one direction, and pushing a piston against a plastic culture dish.50–52 While 92 
these setups replicated many physiological and pathological conditions, they are not ideal for 93 
modeling mechanical stress-induced RPE pathologies since they only achieve a limited range of 94 
attainable strain and do not provide localized application of high levels of stress as would take 95 
place in AMD (Figure 1). The strain experienced by the RPE due to drusen growth and CNV 96 
complications, including vascularization and hemorrhage, can exceed 60%, while the strain 97 
achieved with commercially available models is limited to a maximum of 30%. Moreover, 98 
drusen development occurs chronically over long periods and a realistic model of mechanical 99 
stress in AMD must be able to replicate different rates of strain progression. Thus, there is a need 100 
for a more realistic model of RPE stretching that can replicate different rates and levels of 101 
mechanical stress. 102 
 103 
In the present study, we developed two novel in vitro devices to accurately model mechanical 104 
stress under different modes: In one device, RPE cells were grown on a thin layer of 105 
polydimethylsiloxane (PDMS) which was gradually inflated to mimic chronic increase in 106 
mechanical stress during drusen formation. In another device, cells were grown on porous 107 
membranes of Transwell inserts and a pulse of mechanical stress was added to the membrane to 108 
model acute stress due to CNV. These devices provide easy-to-assemble, customizable and 109 
reliable platforms for studying mechanical stress in adherent mammalian cells. The elastic 110 
properties of the PDMS device allows high levels of stress to be conveyed to cells and the plastic 111 
properties of the Transwell membranes are suitable for static stress experiments. We used these 112 
two devices to study the expression levels of VEGF from RPE cells under varying rates of 113 
mechanical stress and to test the hypothesis that mechanical stretching of RPE cells induces 114 
angiogenesis. An in vitro tube formation assay was used to monitor changes in the length and 115 
junction number of endothelial tubes as an indicator of angiogenic potential of the RPE 116 
secretome. Our results showed an increase in VEGF expression and elevated angiogenic 117 
potential of RPE secretome due to both chronic and acute mechanical stress. 118 
 119 
2. Experimental 120 
2.1 Cell culture 121 
ARPE-19 cells were obtained from American Type Culture Collections (ATCC, Manassas, VA). 122 
Cells between passages 12 and 14 were grown in standard tissue culture treated plates (Thermo 123 
Fisher Scientific, Visalia, CA) using Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 124 
(Hyclone, Logan, UT) supplemented with 10% fetal bovine serum (Hyclone). Growth media 125 
were changed three times per week. Cells were kept in a humidified incubator at 37 °C in 5% 126 
CO2. ARPE-19 cells were grown on the PDMS film of the chronic mechanical stress (CMS) 127 
device and Transwell membranes (Corning, Corning, NY) of the acute mechanical stress (AMS) 128 
device for 10 weeks before performing mechanical stress experiments to allow RPE 129 
differentiation. To assess the angiogenic potential of RPE secretome, HUVECs (Gibco, Grand 130 
Island, NY) were grown in Medium 200 (Gibco) supplemented with Large Vessel Endothelial 131 
Supplement (Gibco) or in spent media from RPE cultures for 6 hours at 37 °C in 5% CO2.  132 
 133 
2.2 Fabrication of the chronic mechanical stress (CMS) device 134 
The CMS device was developed to mimic chronic mechanical stress in the RPE. This device was 135 
assembled from four components (Figure 2). First, a PDMS block with 100 µm wide 136 
microchannels (Figure 3.C) was made using soft lithography (Figure 2.A). Briefly, a photoresist 137 
pattern was produced on a silicon wafer using SU-8 2075 (Figure 2.A), and PDMS prepolymer 138 
(Sylgard 184, Dow Corning, Midland, MI) was poured over the pattern to achieve a thickness of 139 
~5 mm. PDMS was cured in the oven at 85 ˚C for 2 hours and then peeled off of the silicon 140 
wafer (Figure 2.B). Using a biopsy punch, 28 holes with a diameter of 1.5 mm (3 sets of nine 141 
holes, plus one hole for an access port) were punched into the PDMS block (Figure 2.C). Next, 142 
PDMS prepolymer was spin coated at 5000 rpm on a silicon wafer using a spin coater (CEE® 143 
model 200X) and cured at 85 ˚C for 30 minutes to make a PDMS film with a thickness of 36.6 ± 144 
1.4 µm. Incubating for 30 minutes at 85 ˚C was sufficient to cure the PDMS film since the 145 
thickness of the PDMS film was significantly smaller than the PDMS block.  Both the PDMS 146 
block and PDMS film were O2 plasma treated and the film was permanently bound to the top of 147 
the PDMS block to cap the holes (Figure 2.D, 3.A). The capped PDMS block and a glass slide 148 
were O2 plasma treated and the bottom of the block (microchannel side) was bound to the glass 149 
slide (Figure 2.E). PDMS was molded and cured around three plastic cuvettes to produce the cell 150 
culture chamber walls. PDMS wells were bound to the top of the device and around the capped 151 
holes as described above (Figure 2.F). To apply mechanical stress, air was injected to the 152 
microchannels through the access port using a syringe pump to inflate the thin PDMS film 153 




Figure 2. Fabrication of the CMS device. An SU-8 master was made using photolithography 
(A) and PDMS was cured from the master (B). After punching 1.5 mm (diameter) holes in the 
PDMS block (C), a thin PDMS membrane was bound to the top of the PDMS block (D). After 
attaching the device to a glass slide (E), cells were cultured on the PDMS film (F). 
Mechanical stress was applied to cells by inflating the PDMS film using a syringe pump (G). 
(H, I) Fully assembled device. 
 156 
2.3 Fabrication of the acute mechanical stress (AMS) device 157 
The AMS device was made to apply acute mechanical stress to cells cultured on Transwell 158 
membranes (polyester, 10 µm thickness). Transwell membranes are composed of permeable 159 
plastic sheets that support polarized secretion of proteins from cells cultured on them. Apical-160 
basolateral polarization is an important characteristic of RPE cells and can be achieved when 161 
growing cells on Transwell inserts. Four 2.5 µL pipet tips were attached to the plunger tip of a 10 162 
mL syringe using PDMS and the barrel of the syringe was cut at the 3mL mark with a scalpel. 163 
The tips of the pipet tips had an outer diameter of 762.25 ± 13.52 µm and an inner diameter of 164 
369.3 ± 18.54 µm. The syringe with attached pipet tips was placed on a syringe pump. A 20 mm 165 
circle (diameter) was cut from the bottom of the wells of a 6-well plate. 24 mm Transwell inserts 166 
 
Figure 3. The CMS device. (A) The device was assembled and connected to a syringe pump 
using a silicon tubing. (B) Top view of the device showing through holes and the thin PDMS 
film (Arrow). (C) Bottom view of the device showing microchannels connecting the through 
holes. (D-G) Injecting air to the device using a syringe pump inflated the PDMS film. (H-K) 
FEA model of the inflation of the PDMS film in the CMS device. Strain level was highest on 
top of the inflated PDMS film. 
with cells were transferred to the bottomless well plate and the plate was placed on the syringe 167 
pump such that the tips of the pipet tips reached the bottom of Transwell membranes. 168 
Mechanical stress was applied to Transwell membranes by controlling the movement of pipet 169 
tips with the syringe pump (Figure 4.A). Once the membranes were poked with pipet tips (Figure 170 
4.B), they underwent plastic deformation and stretched the cells attached to them (Figure 4.C). 171 
 172 
 173 
2.4 Device characterization 174 
To determine how the RPE elongates due to CNV or drusen formation, tomography images of 175 
deformed RPE layers from primary literature were analyzed using ImageJ software (National 176 
Institutes of Health, Bethesda, MD, USA).53  Depending on drusen size and the size of the CNV 177 
 
Figure 4. Adding mechanical stress to Transwell membranes using the AMS device. (A) 
Schematic of the AMS device. The syringe pump pushes the pipet tips against the Transwell 
membranes placed upside down on a scale. Scale is used to measure the pressure (stress) 
applied to membranes (B) Stretching a 24 mm Transwell membrane using a pipet tip. (C) 
Plastic deformation of the Transwell membrane 1 hour after poking the membrane with pipets. 
(D) FEA model of the AMS device shows the distribution of strain in Transwell membranes 
when poked with a pipet tip. The maximum strain level was on the side of the deformed area. 
(E) Transwell membrane breakage due to excessive stress. The mechanical failure occurs on 
the side of the deformed area (arrow), confirming the FEA results in D. 
area, RPE elongation (measured as the change in the length of the elongated tissue divided by 178 
baseline length) ranged from ~10% to 60% in RPE focal regions.44,54–56 179 
 180 
Uniaxial and biaxial stress-strain curves for both devices were produced to determine whether 181 
these in vitro devices can replicate in vivo strain levels applied to the RPE during AMD (Figure 182 
5). In the CMS device, air was gradually injected to the device to increase the strain (defined as 183 
percent increase in the length and area of the membrane). Changes in the pressure of the inner 184 
chamber of the CMS device was recorded during the injections using a manometer (Universal 185 
Electronics Inc., Taiwan). Using a stereomicroscope, the deformation of the PDMS film was 186 
monitored. The percent change in uniaxial strain was calculated by dividing the change in length 187 
of the stretched section of the film by its initial length. Biaxial strain was calculated by dividing 188 
the change in the area of membrane’s deformed section by its initial area. Area calculation was 189 
performed by making 3D models of membrane deformation based on 2D images of the 190 
membranes using Ansys SpaceClaim software. Stress relaxation curves were also produced to 191 
determine the rate of air leakage from the CMS device by inflating the PDMS film of the device 192 
to the maximum achievable strain (72% uniaxial) and monitoring the deflation of the membrane. 193 
The pressure applied to Transwell membranes in the AMS device was measured by placing the 194 
membranes on a scale and applying mechanical stress using a syringe pump (Figure 4.A). To 195 
calculate the pressure added to the membranes, the readings from the scale were divided by the 196 
area of the tip of the pipet. Similar to the CMS device, percent strain values were calculated for 197 
the AMS device. 198 
 199 
2.5 Finite Element Analysis 200 
Finite element analysis (FEA) was performed using Ansys V19.1 to evaluate strain distribution 201 
on the PDMS film of the CMS and on the Transwell membrane of the AMS device. Boundary 202 
and loading conditions of the FEA models were defined as close to the conditions of the CMS 203 
and AMS devices as possible. Changes in the elastic strain levels were analyzed during the 204 
addition of 2.7 psi pressure to a 36 µm-thick PDMS model (Figure 3.D-K). A 2-parameter 205 
 
Figure 5. Mechanical properties of CMS and AMS devices. (A) Uniaxial stress-strain curve 
for the PDMS film (36.6 ± 1.4 µm) of the CMS device (B) Biaxial stress-strain curve for the 
PDMS film of the CMS device. (C) Uniaxial stress-strain curve for the Transwell membrane 
(10 µm) of the AMS device. (D) Biaxial stress-strain curve for the Transwell membrane of the 
AMS device. Uniaxial (E) and biaxial (F) strain rates for the PDMS film of the CMS device. 
Uniaxial (G) biaxial (H) strain relaxation curves for the PDMS film of the CMS device. Error 
bars represent one standard deviation. 
 
Mooney Rivlin model (C10=21.03 psi, C01=3.63 psi, D1=0 psi-1) was found to accurately 206 
predict the hyperplastic behavior of the CMS device. Plastic strain in the AMS device was 207 
simulated by pushing a hollow disk with an inner diameter of 370 µm and an outer diameter of 208 
760 µm (according to the size of the tip of the pipet tips used in the AMS device) on a 10 um-209 
thick Transwell model to create 1200 psi pressure (Figure 4.D). 210 
 211 
2.6 Enzyme-linked immunosorbent assay 212 
Spent media from control and stressed cultures of ARPE-19 cells was collected 8 and 24 hours 213 
after adding mechanical stress and assayed for VEGF expression using a human VEGF ELISA 214 
kit (Life Technologies, Frederick, MD). Absorbance at 450 nm was measured using a BioTek 215 
Synergy 2 plate reader (BioTek, Winooski, VT). 216 
 217 
2.7 Immunocytochemistry 218 
Immunocytochemistry (ICC) was performed on ARPE-19 cells grown on Transwell membranes 219 
of the AMS device to visualize intercellular junctions. A fluorescein isothiocyanate (FITC) -220 
conjugated anti zonula occludens-1 (ZO-1) antibody (Invitrogen, Carlsbad, CA) was used for this 221 
purpose. Nuclei were stained with NucBlue Live ReadyProbes nucleic acid stain (Thermo Fisher 222 
Scientific). After staining, samples were imaged using an LSM 710 Carl Zeiss confocal 223 
microscope (Jena, Germany). Due to the elastic properties of the PDMS membrane of the CMS 224 
device, stretched membranes revert to their original size after the device is disconnected from the 225 
syringe pump making confocal imaging of chronically stretched cells not feasible. 226 
 227 
2.8 Endothelial tube formation assay 228 
Tube formation assay was performed using an in vitro angiogenesis kit (Gibco) according to 229 
manufacturer’s instructions. Briefly, the bottom of the wells of a 48-well plate were coated with 230 
100 µL of reduced growth factor Geltrex matrix (Gibco) and incubated at 37 ˚C for 30 minutes. 231 
HUVECs were then diluted in spent media from control or mechanically stressed ARPE-19 232 
cultures to make a concentration of 1.25105 cells/mL. 200 µL of cell suspensions were seeded 233 
on Geltrex matrices and incubated for 6 hours at 37 ˚C and in a humidified incubator with 5% 234 
CO2 to induce endothelial tube formation. Next, HUVECs were stained with Calcein AM dye 235 
(Thermo Fisher Scientific) and imaged using an Eclipse TS100 fluorescence microscope (Nikon 236 
Instrument Inc., Melville, NY). Tube length and node numbers were quantified using ImageJ 237 
software. 238 
 239 
3. Results 240 
3.1 Replicating mechanical stress by in vitro devices 241 
Applying different levels of stress to the PDMS film of the CMS device produced up to ~72% 242 
uniaxial and ~193.5% biaxial strain (Figure 5.A, B). The maximum strain achieved with the 243 
AMS device was ~12 % (uniaxial) and ~12.7 (biaxial) (Figure 5.C, D). Strains greater than the 244 
above-mentioned values for each device resulted in punctures to their membranes. Accordingly, 245 
to mimic in vivo RPE elongation, cells were strained from 0 to 60% (uniaxial) over 24 hours in 246 
the CMS device. Using the AMS device, acute mechanical stress (resulting in 10% uniaxial 247 
strain) was applied to cells by pushing an array of four 2.5 µL pipet tips on the bottom of 248 
Transwell membranes 5 times, creating 20 bumps in the membrane. The rate of increase in strain 249 
level in the CMS device was characterized by measuring the uniaxial and biaxial strain every 2 250 
hours for 24 hours and up to a maximum uniaxial strain of 60% (Figure 5.E, F). To examine 251 
whether there was air leakage from the device, deflation of the PDMS film was monitored for 24 252 
hours. Results showed that the strain dropped to ~6.5% (uniaxial) and ~9% (biaxial) after 24 253 
hours due to air leakage (Figure 5.G, H). 254 
FEA results showed that in the CMS device, the top of the inflated PDMS film experiences the 255 
maximum strain level (Figure 3.H-K). The sides of the deformed Transwell membranes of the 256 
AMS device experienced the maximum strain level (Figure 4.D). 257 
 258 
3.2 Enzyme-linked immunosorbent assay and immunocytochemistry 259 
In both the CMS and AMS devices, at 8 hours, there was no significant change in VEGF 260 
expression compared to unstretched controls (Figure 6). At 24 hours, VEGF expression increased 261 
significantly in the CMS device due to chronic mechanical stress. In the AMS device, after 24 262 
hours, VEGF expression increased significantly in both the apical and basal chambers of 263 




Figure 6. ELISA results show elevated VEGF expression in mechanically stressed ARPE-19 
cells. (A) At 8 hours, continuous mechanical stress in the CMS device did not result in 
significant VEGF induction (n=6). 24 hours of 60% chronic strain resulted in a significant 
increase in VEGF expression of cells in the CMS device (n=6). (B) 8-hour application of 
10% acute strain in the AMS device did not result in significant VEGF overexpression (n=6). 
(C) 10% acute strain in the AMS device significantly increased apical and basal VEGF 
expression (n=6). * p<0.05, ** p<0.01, N.S. not significant. Error bars represent one 
standard deviation. 
According to our ICC results, mechanically stretching the RPE by 10% (uniaxial) in the AMS 266 
device disrupts intercellular junctions of APRE-19 cells and creates breaks in the RPE 267 
monolayer (Figure 7). These breaks were located on bumps created by mechanical stress on 268 
Transwell membranes. RPE cells in these areas lacked intercellular ZO-1 localization. Losing 269 
intercellular ZO-1 localization due to the physical disruption of the RPE monolayer correlates 270 
with a statistically significant VEGF overexpression.32 To determine whether the increase in 271 
VEGF expression after adding mechanical stress was due to the disruption of intercellular 272 
junctions and dislocalized ZO-1, we mechanically stressed a subconfluent (2-day-old) ARPE-19 273 
culture using the AMS device and quantified VEGF expression using ELISA. Results showed 274 
that 10% uniaxial strain induced VEGF expression both apically and basally in subconfluent 275 
cultures lacking intercellular junctions (Figure 8). 276 
 277  
Figure 7. Immunocytochemistry of ARPE-19 cells on a stretched Transwell membrane. (A-C) 
Mechanical stress permanently stretched the membrane which created breaks in the RPE, resulting in 
cell-free zones in the middle of the stretched area (arrows). Z-stack images confirm the stretching of the 
membrane in areas with RPE cell-cell detachment (D, z-stack along line α in panel C) and show a 
confluent monolayer in non-stretched area (E, z-stack along line β). Scale bars: 100 µm. 
 278 
3.3 Endothelial tube formation assay 279 
To determine if the increase in mechanical stress can induce angiogenesis, the angiogenic 280 
potential of used media from control and stretched cells in both devices was assessed using an in 281 
vitro angiogenesis kit. Results demonstrate that continually applying mechanical stress within the 282 
CMS device significantly increased the length of endothelial tube-like structures and the number 283 
of junctions (nodes). While the apical media from stressed cultures in the AMS device did not 284 
significantly induce tube formation, basal media significantly increased both tube length and 285 
node number (Figure 9). 286 
 
Figure 8. Mechanical stress induces VEGF expression in subconfluent ARPE-19 cells. 24-hour 
exposure to 10% acute strain in the AMS device significantly induced both apical and basal 
VEGF expression in subconfluent ARPE-19 cells (n=4). ** p<0.01. Error bars represent one 
standard deviation 
 287 
4. Discussion 288 
RPE cells in vivo are exposed to mechanical stress because of drusen formation and CNV during 289 
different stages of AMD. Identifying the effects of mechanical stress on VEGF expression from 290 
RPE cells can lead to a better understanding of the causes of the initiation and progression of 291 
CNV. In previous works, cyclic mechanical stress on RPE cells has been studied.47–50 However, 292 
the pulsatile stretching methodology used in the past cannot replicate chronic and acute 293 
mechanical stress in AMD. Further, the maximum tensile strain achieved by the devices 294 
employed in previous studies is limited (up to 30%), while the tensile strain exerted on RPE cells 295 
during AMD can exceed 60%.54–56,44 Therefore, we sought to develop novel mechanical stress 296 




Figure 9. In vitro angiogenesis assay. (A) Mechanical stress in RPE cells induced endothelial tube 
formation by HUVECs in vitro. (B, C) Endothelial tube length and node number increased when 
HUVECs were exposed to conditioned media from mechanically stressed RPE cells using the CMS 
device (n=4; B) and the basal media of the stretched Transwells in the AMS device (n=4; C). Apical 
media of stretched Transwell cultures failed to change tube length and node numbers significantly 
(n=4). * p<0.05, ** p<0.01, N.S. not significant. Error bars represent one standard deviation. 
The devices developed here provide a tunable platform for studying the role that mechanical 299 
stress plays in various physiological and pathological conditions. Using these in vitro devices, 300 
we replicated chronic and acute mechanical stress on the RPE to test the hypothesis that 301 
mechanical force can lead to CNV by inducing VEGF expression. Both CMS and AMS devices 302 
proved to be reliable, generated reproducible results and were used to study alterations in VEGF 303 
expression in response to acute and chronic mechanical stress (Figure 1). 304 
 305 
VEGF is a key stimulator of aberrant angiogenesis in AMD.16 It has previously been reported 306 
that cyclic mechanical stress can induce VEGF expression in RPE cells.47 However, the 307 
mechanical stress exerted on RPE cells due to drusen formation and CNV is not cyclic – it is 308 
either static or increases with varying rates. In contrast to previous models of mechanical stress, 309 
the devices fabricated here were capable of replicating high levels and different rates of 310 
mechanical stress, nearing those experienced in vivo. These devices more accurately mimicked 311 
the in vivo stretching of RPE cells during different stages of AMD to monitor the alterations in 312 
VEGF expression. According to our ELISA results, both chronic and acute mechanical stretching 313 
of RPE cells is associated with elevated VEGF expression (Figure 6). Besides its role in inducing 314 
angiogenesis, VEGF is also involved in stimulating inflammation and vascular permeability.57–61 315 
Therefore, according to our results, we determined that the initiation and progression of CNV, 316 
and VEGF-induced inflammation in the RPE are, at least in part, due to the mechanical 317 
stretching of the RPE. 318 
 319 
In ARPE-19 cells, a commercially-available RPE cell line, VEGF expression is polarized and 320 
mainly apical.62,63 Mechanical stress devices used in previous studies are not capable of 321 
interrogating differences between apical and basal RPE secretion. Using the AMS device, we 322 
studied polarized VEGF expression in control and mechanically stressed RPE cells. ELISA 323 
results confirmed previous findings with respect to the apical VEGF polarization in ARPE-19 324 
cells, i.e., VEGF expression in 10-week old cultures of ARPE-19 cells was more apical than 325 
basal (Figure 6.C). This observation also indicates that ARPE-19 cells grown on Transwell 326 
membranes were polarized prior to the experiments. ELISA results also showed that mechanical 327 
stress on RPE cells induces VEGF overexpression both apically and basolaterally. While CNV is 328 
induced by the basal VEGF secretion towards the choroid, the apical VEGF secretion can also be 329 
involved in the pathogenesis of CNV since previous studies have shown that apical VEGF 330 
disrupts RPE intercellular junctions and increases permeability in ARPE-19 and primary RPE 331 
monolayers.64 These conditions can facilitate paracellular VEGF transport to the sub-RPE area 332 
towards the choroid, further inducing CNV and facilitating choroidal invasion by creating a 333 
VEGF gradient. 334 
 335 
Elongation of the RPE is often associated with breaks in the RPE monolayer. In AMD, RPE 336 
breaks (also known as RPE tears) occur as a result of CNV formation and follow the detachment 337 
of the RPE from its basal membrane.65,66 In our experiments with the AMS device, we observed 338 
significant breaks in the RPE monolayer and perturbation of intercellular junctions (ZO-1) at 339 
stretched sites when a small and acute strain (10% uniaxial) was applied (Figure 7). ZO-1 is a 340 
tight junction protein that localizes to intercellular spaces of RPE cultures as early as one week 341 
after reaching confluency. Our group and others have previously shown that the disruption of the 342 
RPE integrity can induce VEGF expression.30–32 Thus, it is possible that the elevation of VEGF 343 
expression after adding mechanical stress is partially due to breaks in the RPE monolayer. To 344 
determine whether the increase in VEGF expression was solely a consequence of cell-cell 345 
detachment, we evaluated the effect of mechanical stress on VEGF expression in a 2-day old 346 
ARPE-19 culture. At 2 days of culture, RPE intercellular junctions are not formed, since ARPE-347 
19 cells require at least 1 week after reaching confluency to start establishing intercellular 348 
junctions.32 Therefore, by stretching a subconfluent ARPE-19 culture, we excluded the effect of 349 
alterations in junctional structures. Our results showed elevated VEGF expression in 350 
mechanically stressed subconfluent cultures of ARPE-19 without intercellular junctions (Figure 351 
8), suggesting that mechanical stress independently induces VEGF overexpression, regardless of 352 
the formation of intercellular junctions. 353 
 354 
Overexpression of VEGF by RPE cells is known to induce CNV.16–19 A previous study showed 355 
that even a short-term increase in VEGF expression can result in long-term CNV development,19 356 
suggesting that even temporary mechanical stress on the RPE due to an increase in the size of 357 
drusen may trigger CNV and a short-term increase in the size of neovascular regions may 358 
accelerate CNV. Our results can also explain the presence of high levels of VEGF in drusen 359 
deposits from AMD patients as a result of the mechanical stress experienced by the RPE cells 360 
surrounding the drusen.10 361 
 362 
Finally, we used an in vitro tube formation assay to explore whether mechanical stress can 363 
stimulate the differentiation of endothelial cells to endothelial tube-like structures and to test the 364 
hypothesis that elongating RPE cells can induce angiogenesis. Spent media from cells exposed to 365 
mechanical stress in the CMS device and from the basal chamber of the AMS device promoted 366 
in vitro angiogenesis (Figure 8). Interestingly, the elevated apical VEGF secretion (Figure 6A) 367 
did not result in a statistically significant increase in angiogenesis, suggesting that anti-368 
angiogenic factors may also be upregulated by mechanical stress apically. Given that the basal 369 
secretion of angiogenic proteins by RPE cells is crucial for choroidal angiogenesis, the increase 370 
in the angiogenic potential of the basal media supports the hypothesis that mechanical stress may 371 
be involved in CNV initiation and progression. 372 
 373 
While mechanical disruption of the RPE is a significant aspect of both dry and wet AMD, it has 374 
received limited attention among researchers. This work is the first attempt to develop in vitro 375 
models of acute and chronic mechanical stress on RPE cells and, for the first time, shows a 376 
correlation between RPE stretching and angiogenesis. These findings can help better understand 377 
the mechanisms of initiation and progression of CNV and may lead to the development of more 378 
effective therapeutic interventions. For example, anti-VEGF treatments, currently used to control 379 
the progression of CNV,67–73 may also be considered as a preventative approach by starting anti-380 
VEGF treatments as soon as growth of drusen is detected to lower VEGF levels and therefore 381 
prevent CNV initiation. Treatment strategies can also be optimized by adjusting the dose of anti-382 
VEGF injections according to the amount of stress being exerted to the RPE due to CNV growth 383 
(measured by analyzing tomography images), to more effectively control CNV progression. 384 
 385 
CNV is a complex process and is mediated by multiple pro- and anti-angiogenic factors and 386 
inflammatory cytokines.12,74–76 Given the contribution of mechanical stress in inducing 387 
inflammation in various tissues, further research is required to identify inflammatory cytokines 388 
that are potentially affected by mechanical stretching of the RPE.77–80 The devices presented in 389 
this work can be used for this purpose. In particular, the CMS device can be used to evaluate the 390 
role of different rates of increase in mechanical stress in AMD pathogenesis. According to FEA 391 
results, the inflation of the PDMS film in the CMS device can transmit high levels of strain to 392 
cultured cells with the highest strain conveyed to cells in the middle of the stressed area (Figure 393 
3.H-K). Although we only used the CMS device for chronic stress experiments, different 394 
regimens of stress could be achieved by controlling the rate of air injection. Moreover, the CMS 395 
device could be scaled up when a higher cell density is needed or down when smaller samples 396 
are desired. However, the non-porous basal membrane (PDMS film) of the CMS device does not 397 
allow cell polarization and would need to be modified to support polarized cell growth. Lastly, 398 
our results did show that air leakage from the CMS device results in deflation of the PDMS film. 399 
While air leakage did not significantly affect our experiments, it could interfere with static stress 400 
experiments. Since the device was connected to the syringe throughout our experiments, air 401 
leakage from the syringe is suspected to be the main cause of deflation. To prevent leakage after 402 
reaching the desired strain, the device could be blocked from the syringe by closing a valve 403 
inserted between the device and the syringe. 404 
 405 
When polarization of cells is desired, the AMS device could be employed. A major difference 406 
between the CMS and AMS devices is that the Transwell membrane of the AMS device can 407 
undergo plastic deformation, while the deformation within the CMS device is elastic. While this 408 
property makes the AMS device more suitable for static stress experiments, only a limited range 409 
of strain levels can be achieved with the AMS device compared to the CMS device (up to ~12% 410 
uniaxial in the AMS device compared to ~ 72% uniaxial in the CMS device). Also, to apply 411 
mechanical stress with the AMS device, cultured Transwell membranes must be removed from 412 
culture medium, which limits the length of the time a membrane can be processed and makes the 413 
AMS device unsuitable for long-term and continuous stretching studies. Further work, such as 414 
using a different material with higher plastic deformation properties instead of the Transwell 415 
inserts (polyester), is needed to resolve these shortcomings. In addition, according to our FEA 416 
results, poking the Transwell membranes resulted in a non-uniform distribution of the strain 417 
throughout the membrane, i.e., the sides of the elongated membrane experienced the highest 418 
strain (Figure 4.D). The breakage of the membranes from the sides due to high levels of stress 419 
(Figure 4.E) and the distribution of cells on the membrane after applying mechanical stress 420 
(Figure 7) confirm the findings of our FEA model. Pipet tips of the AMS device could be 421 
replaced with needles with a round tip to achieve a more uniform distribution of strain.  422 
 423 
The rate of increase in strain level due to drusen formation and CNV has not been studied 424 
previously to our knowledge, however in a recent study the rate of increase in the drusen volume 425 
has been shown to be ~0.1% per day or slower.44 Given that the rate of volume progression in the 426 
CMS device was significantly faster (~8.5% per hour), more experiments with exposure times 427 
longer than 24 hours will be needed in the future to more accurately replicate chronic mechanical 428 
stress during drusen formation. 429 
 430 
Besides the role of mechanical stress in inducing growth factor-mediated CNV, the physical 431 
damage that it causes on the RPE can directly impair the supportive functions of the RPE, 432 
leading to the loss of photoreceptors. Previous studies have shown that RPE injury can lead to 433 
retinal degeneration.40,81–83 The indispensable element of the visual system, photoreceptors, rely 434 
on the RPE for trophic and metabolic support.81,84 In future experiments, the devices presented 435 
here can be used to evaluate the effect of mechanical stress on the function of RPE-photoreceptor 436 
complex within in vitro retinal models. 437 
 438 
5. Conclusions 439 
In conclusion, we developed two novel mechanical stress devices to study the role of mechanical 440 
stress in CNV in AMD. Our results show that mechanical stress can induce VEGF expression in 441 
RPE cells and promote in vitro angiogenesis. These results underline the importance of the 442 
mechanical stress in CNV pathogenesis. 443 
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